News - Events

BioFIT is a partnering event in Europe for people negotiating technology transfers, working in academia-industry collaborations and driving early-stage innovation deals in the life sciences. It is also a venue for discussing and learning about pre-seed, seed and Series A investments.

This meeting will look at the regulatory environment for pre-filled syringes which are disposable syringes that contain a single dose of a medication for use by patients. Specifically, this 12^th annual meeting will look new EU medical device regulations which require that marketing authorisation applications for medicines with an integral medical device must include the results of the device’s assessment of conformity by a notified body. This regulation covers pre-filled syringes as well as pens, transdermal drug delivery devices and pre-filled inhalers.

This conference will explore new technologies in pharmaceutical microbiology and well as the regulatory landscape. Microbiology testing describes the use of biological or biochemical methods to detect impurities in a material. In the context of medicine, it often refers to tests to detect pathogens causing human diseases. This industry is expected to see significant growth over the next five years. At the same time, the technology driving the industry is changing rapidly.

The inaugural Disruptive Technologies in Pharma conference will bring together experts of emerging technologies to discover the opportunities for pharma in artificial intelligence, machine learning, the internet of things, digital therapeutics, electronic health and blockchain.

This meeting will focus on issues relating to parallel trade, which is the cross-border sale of pharmaceuticals within the EU by traders outside of the manufacturer’s distribution system without the manufacturer’s consent. Parallel trade is a form of arbitrage which has been upheld by the European Court of Justice as being consistent with the principles of free trade. This meeting will take a look at parallel trade in the context of Brexit and other contemporary legal issues.

This event will focus on the latest research and development in delivery systems for medicines that aim to address difficult targets within the human body. For the first time in this series, delegates will learn about oligonucleotide delivery during an opening 'focus day.' The main conference will focus on current developments in messenger RNA therapeutics as immunotherapies and vaccines.

This conference will explore the use of three-dimensional (3D) cell culture for drug screening and projects involving cell therapy. A 3D cell culture is an artificial environment in which biological cells are allowed to grow and interact with their surroundings in all three dimensions. The discussion will also include advances in organs-on-chips which are three-dimensional microfluidic cell culture chips that mimic the physiological response of entire organs to disease. The chips are a tool for modelling disease and identifying targets for new therapies.

Antimicrobial resistance (AMR) describes the ability of a microorganism like bacteria, viruses and some parasites to stop an antibiotic, antiviral drug or antimalarial drug from working. As a result, standard treatments for many serious diseases become ineffective, the infections persist and an increasing number of people are harmed. A subset of AMR is antibacterial resistance.

BioTrinity is a long-running two-day life sciences conference that will take place in 2020 in central London from 28-29 April. The conference focuses on partnering, investment and collaboration, and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.